|
| Press Releases |
|
 |
|
| Friday, January 19, 2018 |
|
|
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan |
| Sato Pharmaceutical Co., Ltd. obtained marketing and manufacturing approval for the oral antifungal agent NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) for the treatment of onychomycosis in Japan on January 19, 2018. more info >> |
|
|
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046 |
| Eisai Co., Ltd. announced today that it has entered into a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent E7046. more info >> |
|
| Monday, June 3, 2024 |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30: JST
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30 HKT/SGT
|
|
|
正力新能2025年度業績實現爆發式增長 淨利潤增幅近8倍
Apr 8, 2026 11:44 HKT/SGT
|
|
|
三菱重工、NEDO懸賞金活用型プログラム「GENIAC-PRIZE」で第2位を受賞
Apr 8, 2026 11:30: JST
|
|
|
三菱重工グループのCrystal Mover Services、米国アトランタ国際空港のAPMシステム「ATL SkyTrain」の設備更新工事を受注
Apr 8, 2026 11:30: JST
|
|
|
MHI and Algomatic Win Second Place in the NEDO GENIAC‑PRIZE Program
Apr 8, 2026 12:03 JST
|
|
|
Heavyweight Endorsement from Top-tier Cornerstone Investors! Sigenergy (06656.HK) Launches IPO: Led by Temasek and Goldman Sachs, the AI Energy Storage Leader Ignites Hong Kong's New Stock Frenzy
Apr 8, 2026 11:01: JST
|
|
|
Heavyweight Endorsement from Top-tier Cornerstone Investors! Sigenergy (06656.HK) Launches IPO: Led by Temasek and Goldman Sachs, the AI Energy Storage Leader Ignites Hong Kong's New Stock Frenzy
Apr 8, 2026 10:01 HKT/SGT
|
|
|
頂級基石陣容重磅背書！思格新能源（06656.HK）啟動招股：淡馬錫、高盛領銜，AI 儲能領頭羊點燃港股新股熱潮
Apr 8, 2026 10:01 HKT/SGT
|
|
|
首程控股（0697.HK）分紅回購並舉 8年累計回饋股東約68.77億港元
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Shoucheng Holdings (0697.HK) Combines Dividends and Share Buybacks in Tandem, Returning Approximately HK$6.877 Billion to Shareholders Over Eight Years
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Formerra宣佈全球提價
Apr 8, 2026 04:00 HKT/SGT
|
|
|
Formerra宣布全球提价
Apr 8, 2026 04:00 HKT/SGT
|
|
|
Formerra Announces Global Price Increase
Apr 8, 2026 04:00 HKT/SGT
|
|
|
美國馬球協會（USPA）與ESPN攜手呈現標誌性的USPA金杯賽，賽事將在USPA國家馬球中心舉行，由傳奇解說員克裡斯·福勒擔任主持
Apr 7, 2026 19:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
